Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a Healthcare company (Biotechnology) with a market capitalization of $8.5B. The Maz Rating grades it against the other companies in its sector.
Praxis Precision Medicines, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $305.06, Praxis Precision Medicines, Inc. trades at 7.1x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -29.4%, return on invested capital of -32.3% and a free cash flow yield of -3.8%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 14.53. Over the past 52 weeks the share price ranged from $160.11 to $392.70, with a beta of 2.84.
Praxis Precision Medicines, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 14 Buy, 3 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Praxis Precision Medicines, Inc. (PRAX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 14.4% / 30% · Interest income / Revenue 1268000000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.35% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 1268000000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.35% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 1268000000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.02% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 56.7% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 1268000000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 56.8% / 33.33% · (Cash+Recv) / Total Assets 56.8% / 33.33% · Interest income / Revenue 1268000000.0% / 5% | Fail |
No. As of September 2026, Praxis Precision Medicines, Inc. (PRAX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Praxis Precision Medicines, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 1268000000.0% of each dividend: Praxis Precision Medicines, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.